Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0677930 (primary tumor)
 20,210 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Recently, the high mobility group protein gene, HMGIC, was identified as a common genetic denominator in benign tumors with chromosome 12q13-15 aberrations, such as lipomas, uterine leiomyomas, pleomorphic adenoma of the salivary glands, hamartomas of breast and lung, angiomyxomas, and endometrial polyps. In most cases, the rearrangements resulted in the separation of the three HMGIC DNA-binding motifs from the acidic carboxy-terminal tail. Here, we report about the molecular characterization of a case of pleomorphic adenoma carrying a t(1;12)(p22;q15). Studies were performed on a cell line derived from the primary tumor, i.e., cell line Ad-312/SV40. Although the chromosome 12 breakpoint was initially mapped more than 1 Mb distal to the HMGIC gene by fluorescence in situ hybridization (FISH) analysis, the present molecular studies reveal a more complex chromosomal rearrangement that directly affects the HMGIC gene. Using 3'-RACE analysis, a HMGIC fusion transcript was detected that contained the complete HMGIC, coding region but lacked the putative mRNA destabilizing AUUUA motifs that are normally present in the 3'-UTR of HMGIC. Wild-type HMGIC transcripts were also detected in the tumor cells. The results suggest that alterations in the 3'-noncoding region of HMGIC may have to be considered as pathogenetically relevant.
 ...
PMID:Molecular characterization of a complex chromosomal rearrangement in a pleomorphic salivary gland adenoma involving the 3'-UTR of HMGIC. 916 41

Specific chromosomal abnormalities of chromosomal region 6p21.3 have been described in subsets of many benign mesenchymal tumors. In the presented study, we investigated a series of 36 such cases by FISH, and Southern blot analyses for HMGIY rearrangements. FISH results revealed that the chromosomal breakpoints of 11 pulmonary chondroid hamartomas (PCHs), 12 endometrial polyps (EPs), one lipoma, and two uterine leiomyomas (ULs) were located within a 80 kb region surrounding the HMGIY gene. In 11 PCHs and one UL the breakpoints were located 3' of HMGIY, and one PCH showed a breakpoint 5' of HMGIY. Southern blot analyses with intra- and extragenic probes were performed of primary tumor material or cell lines from one UL, three PCHs, and five EPs. In none of these cases was an intragenic rearrangement found. Finally, we were able to detect expression of truncated HMGIY transcripts by 3'-RACE PCR. Our data clearly show the role of a further member of the HMGI family in the development of benign mesenchymal tumors. Although most of the breakpoints of the chromosomal translocations involving HMGIY are located outside the gene, aberrant transcripts resembling the structure of those observed in the case of HMGIC have been found. Our molecular investigations thus led to the identification of the molecular mechanism by which rearrangements of either of two closely related genes lead to the development of frequent benign mesenchymal tumors in humans.
 ...
PMID:HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. 982 99

Gene amplification occurs frequently in human glioblastomas. We report the amplification and expression analysis of glioma amplified sequence 64 (GAS64) which was recently identified by microdissection mediated cDNA capture from the amplicon at 12q13-15. Herein we analyzed primary tumor tissues for amplification frequency and found amplification of GAS64 in 5 out of 49 glioblastomas. The amplification frequency of 10% for GAS64 found among glioblastomas is comparable to the frequency described for other genes from the 12q13-15 amplicon. To isolate the full-length cDNA of GAS64, we performed cDNA library screening and RACE. Sequence analysis of the gene revealed no open reading frame longer than 191 bp suggesting that the RNA may function as a non-translated RNA. Non-translated RNAs have been reported to function on the RNA level as regulators of gene expression. Northern hybridization of GAS64 revealed an increased GAS64 expression in many human glioblastomas with and without GAS64 gene amplification. This is the first report on an amplified and expressed gene with a short open reading frame (ORF). GAS64 may be a candidate gene for regulating gene expression in glioblastomas at the RNA level, possibly through expression of a non-translated RNA.
 ...
PMID:GAS64, the first amplified and putative non-translated gene. 1174 60

The MAP3K8 protooncogene (Cot/Tpl-2) activates the MAP kinase, SAP kinase, and NF-kappaB signaling pathways. MAP3K8 mutations occur in the rat homologue, but activating mutations have yet to be identified in primary human tumors. We have identified MAP3K8 as a transforming gene from a human lung adenocarcinoma and characterized a 3' end mutation in the cDNA. In addition, we confirmed that the mutation occurs in the original lung tumor, and we screened a series of lung cancer cell lines to determine whether the MAP3K8 mutation is a common occurrence in lung tumorigenesis. The oncogene was isolated and identified with the NIH3T3 nude mouse tumorigenicity assay and cDNA library screening. The gene was analyzed by polymerase chain reaction (PCR), single-strand conformational polymorphism (SSCP), and 3'RACE for mutations. The mutation was localized to MAP3K8 exon 8 and confirmed in the primary tumor DNA. Both wild-type and mutant MAP3K8 cDNAs transformed NIH3T3 cells, but the transforming activity of the mutant was much greater than that of the wild type. PCR-SSCP screening of cell line cDNAs identified one silent polymorphism in cell line SK-LU-1. Although we were unable to find additional activating mutations, these data support a role for MAP3K8 activity in cellular transformation, but suggest that mutational activation of the gene is a rare event in lung cancer.
 ...
PMID:Mutational activation of the MAP3K8 protooncogene in lung cancer. 1528 22

Androgen receptor (AR) variants are associated with resistance to anti androgen therapy both in human prostate cancer cell lines and clinical samples. These observations support the hypothesis that AR isoform accumulation is a consequence of selective therapeutic pressure on the full length AR. The Pten deficient prostate cancer model proceeds with well-defined kinetics including progression to castration resistant prostate cancer (CRPC). While surgical castration and enzalutamide treatments yield an initial therapeutic response, Pten-/-epithelia continue to proliferate yielding locally invasive primary tumor pathology. That most epithelium remains AR positive, but ligand independent, suggests the presence of oncogenic AR variants. To address this hypothesis, we have used a panel of recently described Pten-/- tumor cell lines derived from both from hormone intact (E4, E8) and castrated Pten mutants (cE1, cE2) followed by RACE PCR to identify and characterize three novel truncated, amino terminus containing AR variants (mAR-Va, b, c). Variants appear not only conserved throughout progression but are correlated with nearly complete loss of full length AR (AR-FL) at castrate androgen levels. The overexpression of variants leads to enhanced transcriptional activity of AR while knock down studies show reduced transcriptional output. Collectively, the identification of truncated AR variants in the conditional PTEN deletion model supports a role for maintaining the CRPC phenotype and provides further therapeutic applications of this preclinical model.
...
PMID:Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. 2699 59